Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HRMY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
-6%
0.48
vs 0.51
Q2.23
-2%
0.56
vs 0.57
Q3.23
-21%
0.75
vs 0.95
Q4.23
-43%
0.45
vs 0.79
Q1.24
+40%
0.67
vs 0.48
Q2.24
-64%
0.2
vs 0.56
Q3.24
+5%
0.79
vs 0.75
Q4.24
+89%
0.85
vs 0.45
Q1.25
-6%
0.63
vs 0.67
Q2.25
+292%
0.78
vs 0.2
Sales Growth
YoY
Current
Estimates
Q1.23
+40%
119.1M vs 85.3M
Q2.23
+25%
134.2M vs 107M
Q3.23
+37%
160.3M vs 117.2M
Q4.23
+31%
168.4M vs 128.3M
Q1.24
+30%
154.6M vs 119.1M
Q2.24
+29%
172.8M vs 134.2M
Q3.24
+16%
186M vs 160.3M
Q4.24
+20%
201.3M vs 168.4M
Q1.25
+19%
184.2M vs 154.6M
Q2.25
+19%
205.8M vs 172.8M
Return on Equity
QoQ
Q1.23
+7%
0.07
vs 0.12
Q2.23
+7%
0.07
vs 0.07
Q3.23
+8%
0.08
vs 0.07
Q4.23
+6%
0.06
vs 0.08
Q1.24
+7%
0.07
vs 0.06
Q2.24
+2%
0.02
vs 0.07
Q3.24
+8%
0.08
vs 0.02
Q4.24
+8%
0.08
vs 0.08
Institutionnal Ownership
QoQ
Q1.23
224
224
vs 244
-8%
Q2.23
214
214
vs 224
-4%
Q3.23
210
210
vs 214
-2%
Q4.23
225
225
vs 210
7%
Q1.24
211
211
vs 225
-6%
Q2.24
223
223
vs 211
6%
Q3.24
235
235
vs 223
5%
Q4.24
250
250
vs 235
6%
zacks.com
8 hours ago
businesswire.com
8 hours ago
Quote Panel
Key Metrics
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
NASDAQ
0.18Â ( 0.61%)
Relative Strenght
32
Volume Buzz
-56%
Earning Acce
Yes
Dist 52w H.
29%Forecast
318%2025-Revenue
261%2025-EPS
254%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
UBS
initialisePrevious: Not converted
2024-09-09
Now: Buy
Citigroup
initialisePrevious: Not converted
2024-06-20
Now: Buy
Jefferies
upgradePrevious: Not converted
2022-10-14
Now: Buy
Zacks Investment Research
upgradePrevious: Not converted
2022-04-26
Now: Hold
Relative Strength
HRMY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How HRMY compares to sector?
